Kush Parmar - 14 Nov 2025 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: TRDA
Reported as of: 14 Nov 2025
Net transaction value: -$1,760,000
SEC form: 4
Accepted by SEC: 18 Nov 2025, 16:36:30 UTC
Prior SEC filing: 11 Jul 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Kush Parmar

Key filing fact

Kush Parmar filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 18 Nov 2025.

Key facts

This page summarizes Kush Parmar's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Nov 2025, 16:36.

Change

Previous filing in this sequence was filed on 11 Jul 2025.
Current net transaction value: -$1,760,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001664281 Primary reporting owner

PARMAR KUSH

Relationship: Director, 10%+ Owner
Address: C/O 5AM VENTURE MANAGEMENT, LLC, 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO
Signature: /s/ Kush Parmar
Signature date: 18 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRDA transaction

Common Stock

Sale

Transaction value: $1,760,000
Shares: -200,000
Change %: -6.3%
Price: $8.80
Shares after: 2,963,066
Date: 14 Nov 2025
Ownership: By 5AM Ventures V, L.P.
Footnotes: F1, F2

TRDA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,093,313
Date: 14 Nov 2025
Ownership: By 5AM Opportunities I, L.P.
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.

Footnote F3

Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.